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Vascular calcification: Not so crystal 
clear
WC O’Neill1
Patients with renal failure are predisposed to calcification of the medial 
layer of arteries. This calcification is far more complex than simple 
precipitation of calcium and phosphate and involves multiple forms of 
calcium phosphate. Like bone, calcification in the vessels also involves 
biologic events . The two are necessarily linked and unraveling the 
pathophysiology will require an understanding of both.
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Renal replacement therapy was clearly 
one of the medical marvels of the 
twentieth century, but as we enter the 
twenty-fi rst century it is apparent that 
this has come at the cost of a huge bur-
den of accelerated vascular disease. 
One component of this is medial vas-
cular calcifi cation, a process also termed 
Monckeberg’s arteriosclerosis. This 
must be distinguished from neointimal 
calcifi cation in atherosclerosis, a patho-
physiologically diff erent process that 
can coexist with medial calcifi cation in 
renal failure. Medial vascular calcifi ca-
tion results from both physicochemi-
cal and biologic events, but the former 
have been largely ignored during rush to 
focus on the latter. Th is is unfortunate, 
because the two are closely linked, and 
the biology of vascular calcifi cation is 
necessarily constrained by its physical 
chemistry. Th e report by Verberckmoes 
et al.1 (this issue) refocuses us on the 
physical chemistry, showcasing a pow-
erful tool that can discern the structure 
of calcium deposits at the microscopic 
level. Although not new, the fi ndings 
serve to remind us that the physi-
cal chemistry is far more complicated 
than simple precipitation of calcium 
and phosphate.
Ectopic calcification consists prin-
cipally of noncrystalline (or amor-
phous) calcium phosphate, whitlockite 
([Mg,Ca]3[PO4]2), and apatite, with 
apatite being the predominant crystal-
line form in vessels. Although commonly 
referred to as hydroxyapatite, the apatite 
is actually a Mg-substituted carbonate 
apatite, (Mg,Ca)10(PO4,CO3)6(OH)2. Th e 
physical chemistry of apatite provides a 
useful framework for understanding 
vascular calcifi cation (Figure 1). Apa-
tite does not form directly from calcium 
and phosphate in solution.2 Instead, 
CaHPO4·2H2O is formed, a reversible 
reaction with a solubility product above 
the product of free Ca2+ and HPO4
2– in 
the plasma of most patients with renal 
failure. Th e CaHPO4·2H2O spontane-
ously and gradually transforms, pos-
sibly through other intermediates such 
as octacalcium phosphate, into apatite, 
which is very insoluble under physiologic 
conditions. In vivo, this latter reaction is 
prevented by physiologic levels of two 
well-established inhibitors of calcifi ca-
tion, pyrophosphate (PPi) and matrix Gla 
protein (MGP). PPi binds very tightly to 
hydroxyapatite, preventing further crys-
tallization. MGP probably has a similar 
action by virtue of its γ-carboxylation. 
Mutations that reduce or eliminate PPi 
or MGP lead to extensive vascular calci-
fi cation in both mice and humans.3,4
Th e relative importance of these two 
inhibitors is unclear. We have shown that 
removal of PPi is suffi  cient to produce 
calcifi cation of aortae cultured in medium 
without serum,5 and Price and colleagues 
have found that warfarin, which presum-
ably prevents γ-carboxylation of MGP, is 
suffi  cient to produce calcifi cation of ves-
sels cultured with serum.6 Th e fact that 
vascular calcifi cation occurs when inhibi-
tors are absent implies that there are local 
factors that favor formation of CaHPO4 
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Figure 1 | Formation of apatite is at least a two-step process that begins with formation of 
amorphous calcium phosphate followed by spontaneous conversion to apatite. The first 
reaction does not occur at normal plasma concentrations, which are below the solubility product 
for CaHPO4. The second reaction is essentially irreversible at physiologic pH and is normally 
inhibited in vivo. Thus, ectopic calcification requires factors that favor the first reaction and abrogate 
inhibition of the second reaction.
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at Ca and HPO4
2– concentrations that are 
below its solubility constant in solution. 
Components of the vascular matrix such 
as elastin, which calcifi es spontaneously 
in vitro and is the site of medial calcifi ca-
tion in vivo, and glycosaminoglycans are 
likely contributors.
Th e etiology of vascular calcifi cation in 
renal failure is unclear and is almost cer-
tainly multifactorial. Hyperphosphatemia 
clearly favors formation of CaHPO4, but 
changes in PPi and possibly MGP must 
also occur to allow hydroxyapatite to 
form. We have found that plasma PPi lev-
els are reduced in hemodialysis patients7 
and have shown that PPi hydrolysis is 
increased in uremic aortae because of 
upregulation of alkaline phosphatase (P. 
Garg, K. Lomashvili, and W.C. O’Neill, 
2005, American Society of Nephrology, 
abstr. F-FC)72, ASN Renal Week 2005). 
Thus deficiency of PPi may underlie 
vascular calcification in renal failure 
(Figure 2). Th e upregulation of alkaline 
phosphatase may be a component of the 
osteogenic differentiation of vascular 
smooth muscle cells that has been pro-
posed to occur as a result of uremia or 
hyperphosphatemia.8 MGP, on the other 
hand, is not deficient and is actually 
upregulated in uremic vessels, particu-
larly at sites of calcifi cation. A possible 
explanation for this apparent paradox is 
a reduction in its γ-carboxylation, but this 
has not been examined in renal failure. 
An additional factor may be alkalemia, 
which favors formation of both CaHPO4 
and hydroxyapatite and which increases 
in vitro calcifi cation in aortae at levels 
observed in blood aft er hemodialysis.9
So, where do the findings of Ver-
berckmoes et al.1 fi t in? In addition to 
the expected apatite and amorphous 
CaHPO4, they also detected Mg and 
specifi cally Mg-containing whitlockite 
in the calcium deposits of uremic ves-
sels. Some of this Mg was undoubtedly 
present in hydroxyapatite. Whitlockite 
never occurs in a pure calcium form, 
containing instead varying amounts of 
magnesium. Th e whitlockite was found 
exclusively in the vitamin D-treated rats 
with remnant kidneys, which also had 
more amorphous CaHPO4 and Mg in 
their aortae. Th is is not unexpected, as 
Mg2+ inhibits formation of apatite and 
stabilizes amorphous calcium phos-
phate.10 Unfortunately, the type, degree, 
and duration of renal failure, as well as 
the calcium and phosphate content of 
the diet, diff ered between the two ani-
mal groups, so it is difficult to draw 
any fi rm conclusions about the reason 
for the diff erent forms of calcifi cation. 
However, it is likely that the fi ndings can 
be explained by higher Mg levels in the 
vitamin D-treated rats. Although serum 
Mg levels were similar in the two mod-
els, this may not refl ect tissue levels, and 
the single time point (presumably at the 
end of the study) may not be indicative 
of earlier levels. 
Th e signifi cance of the whitlockite and 
the diff erent proportions of amorphous 
calcium phosphate and poorly formed 
hydroxyapatite is unclear. Whitlockite 
and apatite are equally insoluble, but 
deposits of amorphous calcium phos-
phate are more soluble and thus poten-
tially reversible. Certainly it is clear that 
not all vascular calcifi cation is apatite, 
but this is hardly surprising. Th e signifi -
cance of the report of Verberckmoes et 
al.1 lies instead in the ability to analyze 
discrete calcium deposits at a micro-
scopic level. Th is is important because 
of the focal and heterogeneous nature of 
vascular calcifi cation. Because this tech-
nique requires a synchrotron, its avail-
ability will unfortunately be very limited. 
However, it is hoped that future studies 
with this technique, coupled with other 
studies in uremic vessels, will help crys-
tallize our knowledge of uremic vascular 
calcifi cation.
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Figure 2 | Potential mechanisms for vascular calcification in renal failure. Pyrophosphate 
(PPi) and Matrix Gla protein (MGP) are key inhibitors of apatite formation. PPi may be deficient in 
uremic vessels by virtue of hydrolysis to orthophosphate (Pi) increased alkaline phosphatase (Alk 
phos) activity. Decreased carboxylation of MGP could contribute to apatite formation, but whether 
this occurs in uremia is unknown. Alkalemia at levels that occur after hemodialysis favors both 
reactions and increases calcification of vessels in vitro. Lastly, Mg2+ stabilizes amorphous calcium 
phosphate and can drive formation of whitlockite.
